This study randomized 381 patients with locally advanced, unresectable NSCLC after receiving either sequential or concurrent platinum‐based chemoradiation to placebo or maintenance sugemalimab, a novel PD‐L1 antibody with enhanced immunologic tumor presentation activity. This evidence concerns the gene CD274 and neoplasm.